The hottest money flows into heart medical devices

  • Detail

A large amount of hot money flowed into the "heart" medical device development hot

a recent statistical report shows that in 2007, venture investors invested $1billion to develop medical devices, drugs and other related products for cardiovascular diseases. However, in the past year, the speed of venture capital investment in new projects has also slowed down with the slowdown of economic development

cardiovascular disease has always been the largest killer of human life, and naturally is the main direction of investment in the pharmaceutical industry

however, in recent years, with the increasing number of tumor occurrence and death, in some countries and regions, tumor has become the first factor of death, and antineoplastic drugs have become the focus of development. The reasons why the development of tumor drugs is popular include: the short development cycle, the high probability of success, and the large individual differences of tumors, which lead to more drugs that can be accommodated in the market. In particular, the success of Avastin makes antineoplastic drugs become the focus of attention and investment darling of most companies and investment circles

is the development and return on investment of cardiovascular projects relatively reduced

should not! First of all, because people live longer and longer, cardiovascular disease is still the most common disease in an aging society. Although there are many cardiovascular drugs, the medical needs in this area are far from being met by the high technology intensity of new materials. For example, according to the latest report of the American College of Cardiology, in the United States, 25% of patients with hypertension do not work after using almost all antihypertensive drugs. Developing drugs or other treatments for this stubborn hypertensive disease is still a major task and challenge for the pharmaceutical industry

from the perspective of investment hotspots and trends, R & D projects of cardiovascular diseases maintain a good momentum. Because it is not only necessary but also has a great market prospect to develop cardiovascular therapeutic and preventive drugs with high efficiency, low side effects and economic benefits. Cardiovascular drugs have always been regarded as blockbuster drugs. The best-selling drug in the world is Lipitor, a cardiovascular drug that reduces blood lipids. Although Pfizer's new drug to improve high-quality cholesterol failed last year, its attempts to this kind of drug have never given up or stopped

however, the development cycle of new cardiovascular drugs is getting longer and longer, the requirements are getting higher and higher, and the approval is becoming more and more difficult. Simple safety and effectiveness are not enough to convince FDA and review experts. More convincing clinical data, such as hard indicators such as reducing mortality and stroke, are needed to win favor

relatively speaking, medical device development projects for the diagnosis and treatment of cardiovascular diseases are relatively popular, because there is a large space, a high success rate, less investment, and a short development cycle. This may be the main reason why small and medium-sized companies actively develop such products

when the stock market and economic conditions are bad, investors are certainly more cautious, which is determined by avoiding risks and capital seeking profits. Even very professional investment and development cannot escape the pressure of economic slowdown

at present, in terms of cardiovascular product development, the amount of venture capital in 2008 will be less than that in 2007, which is related to the overall slowdown of venture capital investment. If the investment rate in the cardiovascular field can be maintained in the first five months, the investment in this field in 2008 will still be greater than that in 2005, thus becoming a small harvest year

and we have reason to believe that as long as the aging of the population continues, as long as the heart is beating, the efforts in cardiovascular disease will continue and strengthen

a device: "convenience card" boiling

in the past five years (as of December 31, 2007), nearly $3billion of venture capital has been used to fund small and medium-sized enterprises to develop medical equipment, drugs and other treatment measures related to cardiovascular diseases. During this period, 137 companies were announced to be established, including 72 companies that invested in the development of medical equipment

among these companies, some are mainly engaged in the application of wireless technology for cardiovascular diseases. The difference between it and conventional electronic universal testing machine is that its control mode can be load control. The most striking is the establishment of cardio MEMS company to avoid polishing fabric grinding too fast. In 2000, do not touch it directly with your hand. The company has a strong technology platform, focusing on improving the symptoms of patients with severe chronic cardiovascular diseases, such as aneurysms, congestive heart failure and hypertension. One of the company's successful products is millimeter level micro sensors. The built-in configuration of the micro sensor is only in the range of nanometers to microns, which can effectively and stably carry out various measurements in the body. Micro sensors are permanently implanted into the body through minimally invasive surgery, and have been successfully implanted into more than 3500 patients

in the early stage of its establishment, cardio MEMS company made full use of government loan funds to purchase necessary high-tech laboratory equipment for the research headquarters and laboratories under construction, and making good use of government resources is the best way for innovative enterprises to effectively finance in the initial stage. At the end of 2007, cardio MEMS successfully raised $33million

in fact, in January 2007, cardio MEMS submitted its initial public offering plan of $86million to the public, but announced the cancellation of the above plan in May last year, because the public capital market lacked attractive financing conditions for the company at that time. But the question is, one year later, when the entire capital market is shrouded in the financial crisis caused by the subprime mortgage, can the company still encounter a better listing atmosphere

however, in March this year, another company that has operated in this field for many years successfully completed its initial public offering. Cardionet, a supplier of wireless mobile heart monitoring equipment, focuses on the diagnosis and treatment of arrhythmias. Before its IPO, cardionet spent more than seven years raising nearly $200million in private debt and stocks, and raised nearly $83million in its initial public offering

cardionet has formed a set of comprehensive technologies and services: telemetering mobile heart patients at any time and place, monitoring heartbeat, analysis and induction with ECG

in March 2007, the company made two major advances: the results of a randomized controlled clinical trial of more than 300 outpatient patients showed that for patients with negative or insufficient dynamic electrocardiogram monitoring, the detection rate of arrhythmia by cardionet system was three times that of traditional monitoring equipment; In the same month, cardionet acquired pdshow, a medical service provider with 150000 patients in 49 states in the United States

cardionet believes that its products and services have reached a penetration rate of 5% in a market of about $2billion

Copyright © 2011 JIN SHI